Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDFH: LDLR mRNA Exosomes for HoFH
NCT05043181Phase 1Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of LDLR mRNA exosomes in homozygous familial hypercholesterolemia (HoFH), sponsored by Tangdu Hospital. Primary endpoint: Changes of Total Cholesterol at Day 19. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
LDLR mRNA exosomes
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT05043181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043181.